TOMDF
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2022 Q4 | -0.00 | $1M | $883,898 |
| 2022 Q3 | -0.00 | $2M | $580,000 |
| 2022 Q2 | -0.01 | $2M | -$1M |
| 2022 Q1 | -0.01 | $2M | -$2M |
| 2021 Q4 | -0.03 | $4M | -$2M |
| 2021 Q3 | -0.01 | $1M | -$4M |
| 2021 Q2 | 0.01 | $2M | -$3M |
| 2021 Q1 | -0.04 | $5M | -$4M |